Uncategorized
Issues with safety of anti-VEGF agents in infants with ROP call for further investigation
VIENNA — Increasing evidence supports the efficacy of anti-VEGF agents in the treatment of retinopathies, but safety concerns remain with their use in infants, requiring further investigation, according to a specialist speaking at the Advanced Retinal Therapy meeting. Focusing on retinopathy of prematurity, Mary Elizabeth Hartnett, MD, said that multiple case series and small trials as well as the BEAT-ROP study found efficacy in reducing intravitreal neovascularization and facilitating physiologic retinal vascular development in some cases.